Welcome to our dedicated page for PARKERVISION SEC filings (Ticker: PRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PARKERVISION's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PARKERVISION's regulatory disclosures and financial reporting.
ParkerVision, Inc. files a Prospectus Supplement and attaches a Form 8-K to update its resale registration covering 17,189,660 shares of Common Stock. The supplement reconfirms resale registrations tied to prior private placements, a PIPE agreement with Aspire Capital, and convertible notes from 2018. The company will not receive proceeds from selling holders; issuer proceeds may occur only if certain warrants or PIPE-related instruments are exercised. The Form 8-K also discloses a Compensation Committee action to extend the expiration dates of previously awarded nonqualified stock options for CEO Jeffrey Parker (2,660,000 options) and CFO Cynthia French (870,550 options) from August 7, 2026 to August 7, 2029, with an unchanged exercise price of $0.171 per share. The company expects to record a one-time non-cash share-based compensation charge of approximately $360,000 related to the modification.
ParkerVision, Inc. supplements its April 19, 2019 prospectus to register 12,800,000 shares of Common Stock for resale by selling stockholders, consisting of up to 7,800,000 shares issuable on conversion of convertible promissory notes and 5,000,000 shares issuable upon exercise of a five-year warrant. The company will not receive proceeds from the resale; if the warrant is exercised for cash, the company would receive up to $800,000 to be used, if received, to fund patent enforcement actions and for general corporate purposes. The supplement also attaches a Form 8-K disclosing that the Compensation Committee approved an extension of the expiration dates of certain fully vested nonqualified stock options for the CEO and CFO from August 7, 2026 to August 7, 2029, which the company expects will result in a one-time non-cash share-based compensation charge of approximately $360,000.
ParkerVision, Inc. disclosed that its Compensation Committee approved changes to outstanding nonqualified stock options held by CEO Jeffrey Parker and CFO Cynthia French. The company extended the options’ expiration date from August 7, 2026 to August 7, 2029 to maintain their long-term incentive value.
The modified awards cover 2,660,000 options for Mr. Parker and 870,550 options for Ms. French, all originally granted on August 7, 2019 with an exercise price of $0.171 per share. These options were fully vested as of the modification date.
ParkerVision expects to record a one-time, non-cash share-based compensation charge of approximately $360,000 related to this modification. Only the expiration dates were changed; the exercise price, number of shares, vesting status, and all other terms remained the same, and no additional securities were issued.
ParkerVision, Inc. is registering for resale 9,387,500 shares of Common Stock under a prospectus supplement dated March 23, 2026, consisting of shares issued, shares issuable upon conversion of convertible notes, and shares issuable upon exercise of options.
The supplement states the company will not receive proceeds from selling shareholders; if the 200,000 Options are exercised for cash, the company would receive up to $42,620. The supplement attaches the company’s Form 10-K for the fiscal year ended December 31, 2025.
As context, shares outstanding were 147,535,024 as of March 19, 2026. The filing is a resale registration by selling holders under the existing Prospectus (Prospectus dated May 11, 2023).
ParkerVision, Inc. registers 16,638,353 shares of common stock for resale pursuant to a Prospectus Supplement dated March 23, 2026.
The shares are issuable upon conversion of convertible promissory notes dated between May 10, 2022 and August 3, 2022 at a fixed conversion price of $0.13 per share and are being resold by selling shareholders (resale offering). The Prospectus Supplement attaches the company’s Form 10-K for the fiscal year ended December 31, 2025 and updates disclosures.
Context: the company reported 147,535,024 shares outstanding as of March 19, 2026, cash and cash equivalents of $4.4M as of December 31, 2025, and convertible notes principal of $3.1M as of that date.
ParkerVision, Inc. registers 1,578,946 shares of Common Stock for resale under a prospectus supplement dated March 23, 2026. The registration consists of 1,052,631 shares of Common Stock and 526,315 shares issuable upon exercise of outstanding warrants. The company will not receive proceeds from resales by the selling stockholder; if the warrants are exercised for cash, ParkerVision would receive up to $526,315, which it expects to use for general working capital, including payment of litigation expenses.
The supplement incorporates ParkerVision’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and updates the prospectus’ disclosures regarding the company’s patent enforcement-focused business, contingent funding arrangements, convertible debt, and substantial doubt about its ability to continue as a going concern.
ParkerVision, Inc. is registering 13,342,953 shares of Common Stock for resale by selling stockholders under a prospectus supplement dated March 23, 2026.
The registered shares consist of 7,962,722 shares issued under earlier purchase agreements, 3,230,942 shares and 1,619,289 shares underlying warrants issued in March 2021, and 530,000 shares issued for services. The company will not receive proceeds from resale by the selling stockholders, but could receive up to $2,833,756 if the Warrants are exercised for cash; any such proceeds are expected to be used for general working capital, including payment of litigation expenses.
This prospectus supplement updates the Prospectus (dated April 26, 2021) with information from the Company’s Annual Report on Form 10-K filed March 23, 2026. Shares outstanding were 147,535,024 as of March 19, 2026.
ParkerVision, Inc. files a prospectus supplement to register the resale of 5,871,584 shares of Common Stock. The resale consists of shares issued under securities purchase agreements dated April 29, 2020 through August 19, 2020, and the company will receive no proceeds from sales by the selling stockholders.
The supplement attaches the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and updates the base prospectus; it references patent-enforcement-driven licensing efforts, contingent funding arrangements, and going-concern disclosures in the attached Form 10-K.
ParkerVision, Inc. is registering 16,809,295 shares of its common stock for resale by the selling stockholders under a Prospectus Supplement dated March 23, 2026. The resale pool includes shares issuable on conversion of notes, shares issued under purchase agreements and as consideration, and shares issuable upon exercise of warrants.
The company states it will not receive proceeds from sales by the selling stockholders; however, if the Aspire and Tailwinds warrants are exercised for cash, the company would receive up to $3,900,000. Shares outstanding were 147,535,024 as of March 19, 2026.
ParkerVision, Inc. registers 18,014,164 shares of Common Stock for resale by selling stockholders under a prospectus supplement dated March 23, 2026. The registered shares consist of conversions of convertible notes, shares issued for services, and a warrant exercisable into up to 1,800,000 shares.
The company states it will not receive proceeds from sales by the selling stockholders; however, if the Park Consulting Warrant is exercised for cash the company would receive up to $180,000 in gross proceeds. This supplement attaches the company’s Form 10-K for the fiscal year ended December 31, 2025 and updates the prospectus with those disclosures.